Investment case

Bristol-Myers Squibb Company

BMY · 30 developments mapped · last assessed 2026-09-29

Market Ontology has mapped 30 macro, policy, and market developments to Bristol-Myers Squibb Company since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

Last close

Unavailable

No published quote

Market cap

Unavailable

Equity value

Diluted shares

Unavailable

Latest reported

Sector

Unavailable

Listing

Unavailable

Filings

Unavailable

No published filing

Valuation

No validated run has been published for BMY yet, so no modelled value is shown. The BMY valuation is in the public catch-up queue.

Subscribers do not wait for the weekly cycle: they run BMY on demand, against live prices and the latest filings, and change any assumption the developments below move.

Filed financials

A validated filed-statement snapshot has not been published for BMY. Missing data is not estimated or replaced with scenario assumptions.

Continue this research

Value BMY on your own assumptions

Run the valuation on Bristol-Myers Squibb Company, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run BMY on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade BMY

Professional

Open trade discovery with Bristol-Myers Squibb Company and BMY already in context.

Open

Find pricing gaps in BMY

Institutional

Open relative-value and arbitrage analysis with BMY already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens BMY first, then any listed company you want to value or monitor.

Choose another company

Current case

Strongest support
Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
Direct financial performance and strategic execution validation.
2026-09-21 · Moves revenue growth rate, profitability margins, risk premium (due to reduced patent cliff exposure)
Main threat
Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial
Increased competition in the multiple sclerosis market. Potential market share erosion for existing MS drugs or pipeline assets.
2026-09-01 · Moves market share for existing ms drugs (e.g., zeposia), pricing power in the ms market
Open question
Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration
Direct impact on future revenue streams and profitability due to patent expiration and new drug commercialization efforts.
2026-08-30 · Moves long term growth rate, terminal value growth rate, discount rate (reflecting risk of pipeline execution)

What changed, by assumption

Revenue growth rate

2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge
2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix
2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth
2026-09-21Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surge

Revenue growth rate (near term)

2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2
2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue following Q2 EPS surge
2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Q2 Revenue

Long term growth rate

2026-08-30Bristol Myers Squibb Positions Replacement Portfolio Ahead of 2028 Eliquis Expiration

Market share for existing ms drugs (e.g., zeposia)

2026-09-01Novartis Remibrutinib Meets Primary Endpoint in Phase III MS Trial

Market share projections for zeposia (ozanimod)

2026-09-01Novartis BTK Inhibitor Remibrutinib Succeeds in Phase III MS Trials

Assumption changes

Full ledger →

Date	Assumption	Direction	Why	Conf.
2026-08-06	Valuation multiple	Bullish	Target re-rates to bid premium until close.	0.70

Event impact log

Full ledger →

Date	Mechanism	Direction	Horizon	Impact
2026-09-29	Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer	watch	3-12m	0.10
2026-09-29	Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer	watch	3-12m	0.30
2026-09-26	C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data	watch	3-12m	0.20
2026-09-26	C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS	watch	3-12m	0.20
2026-09-25	Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR	watch	3-12m	0.20
2026-09-25	Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery	watch	3-12m	0.20
2026-09-24	Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026	Bullish	3-12m	0.30
2026-09-24	HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026	Bearish	3-12m	0.35
2026-09-21	Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix	Bullish	3-12m	0.80
2026-09-21	Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge	Bullish	3-12m	0.90
2026-09-21	Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth	Bullish	1-3m	0.80
2026-09-21	Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surge	Bullish	1-3m	0.80

Value BMY yourself$399/month

Continue this research

Value BMY on your own assumptions

Run the valuation on Bristol-Myers Squibb Company, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run BMY on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade BMY

Professional

Open trade discovery with Bristol-Myers Squibb Company and BMY already in context.

Open

Find pricing gaps in BMY

Institutional

Open relative-value and arbitrage analysis with BMY already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens BMY first, then any listed company you want to value or monitor.

Choose another company

Bristol-Myers Squibb Company

BMY · 30 developments mapped · last assessed 2026-09-29

Value BMY on your own assumptions

Run the valuation on Bristol-Myers Squibb Company, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run BMY on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade BMY

Professional

Open trade discovery with Bristol-Myers Squibb Company and BMY already in context.

Open

Find pricing gaps in BMY

Institutional

Open relative-value and arbitrage analysis with BMY already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens BMY first, then any listed company you want to value or monitor.

Choose another company

Date

Assumption

Direction

Why

Conf.

2026-08-06

Valuation multiple

Bullish

Target re-rates to bid premium until close.

0.70

Date

Mechanism

Direction

Horizon

Impact

2026-09-29

Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer

watch

3-12m

0.10

2026-09-29

Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer

watch

3-12m

0.30

2026-09-26

C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker Data

watch

3-12m

0.20

2026-09-26

C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMS

watch

3-12m

0.20

2026-09-25

Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACR

watch

3-12m

0.20

2026-09-25

Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery

watch

3-12m

0.20

2026-09-24

Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026

Bullish

3-12m

0.30

2026-09-24

HUTCHMED and AstraZeneca present Phase III lung cancer data at ESMO 2026

Bearish

3-12m

0.35

2026-09-21

Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of Mix

Bullish

3-12m

0.80

2026-09-21

Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue Following 153% EPS Surge

Bullish

3-12m

0.90

2026-09-21

Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growth

Bullish

1-3m

0.80

2026-09-21

Bristol Myers Squibb growth portfolio hits 60% of revenue after Q2 profit surge

Bullish

1-3m

0.80

Value BMY on your own assumptions

Run the valuation on Bristol-Myers Squibb Company, change any assumption the events above move, and see the price that falls out.

Public valuations here are refreshed weekly and only published once a run passes every validation check. Subscribers run BMY on demand instead, against live prices and the latest filings.

Subscribe to value any ticker

Opportunities created

Research workflows

Trade BMY

Professional

Open trade discovery with Bristol-Myers Squibb Company and BMY already in context.

Open

Find pricing gaps in BMY

Institutional

Open relative-value and arbitrage analysis with BMY already in context.

Open

Professional actions continue at $399/month. Institutional arbitrage requires the $399/month tier.

$399/month · charged today · cancel anytime. Opens BMY first, then any listed company you want to value or monitor.

Choose another company